Quest Diagnostics Incorporated(DGX) is having a Dividend Yield of 1.89% with the Annual cash Dividend per share of $1.58. Quest Diagnostics Incorporated has a 5 year average dividend yield of 1.89% and the stock has a Indicated annual dividend of $1.8. Quest Diagnostics Incorporated(DGX) formally announced its most recent dividend on November 21, 2016 with a Dividend per share of $0.45. The new indicated annual dividend based on announced dividend per share is $1.8. The dividend yield based on the forward looking indicated annual dividend is 1.89%. Quest Diagnostics Incorporated(DGX) has the most recent dividend payout ratio of 0.31 with a 5-year average payout ratio of 0.28. Companys change in pay out ratio when compared to the last 5 years average pay out ratio has been 0.03. The 5 year historical dividend growth of Quest Diagnostics Incorporated(DGX) is at the rate of 20.22% while the R-Squared dividend growth is 0.78. If the value of R-Square is close to one, it indicates a perfect fit and the higher value conforms to the regression line while data close to zero indicates the opposite.
Quest Diagnostics Incorporated (NYSE:DGX) witnessed a decline in the market cap on Thursday as its shares dropped 0.09% or 0.09 points. After the session commenced at $95.58, the stock reached the higher end at $96.45 while it hit a low of $94.9. With the volume soaring to 761,688 shares, the last trade was called at $95.3. The company has a 52-week high of $96.45. The company has a market cap of $13,056 million and there are 137,000,000 shares in outstanding. The 52-week low of the share price is $61.92. Shares of Quest Diagnostics Incorporated rose by 1.63% in the last five trading days and 2.52% for the last 4 weeks. Quest Diagnostics Incorporated is up 12.4% in the last 3-month period. Year-to-Date the stock performance stands at 4.21%.
Currently the company Insiders own 1.5% of Quest Diagnostics Incorporated shares according to the proxy statements. Institutional Investors own 87.71% of Quest Diagnostics Incorporated shares. During last six month period, the net percent change held by insiders has seen a change of -37.76%. Company has reported several Insider transactions to the SEC, on Feb 15, 2017, Michael E Prevoznik (SVP & General Counsel) sold 1,200 shares at 93.76 per share price.On Feb 1, 2017, Catherine T. Doherty (SVP, Clin. Franchise Solutions) sold 80,000 shares at 90.81 per share price.On Nov 17, 2016, Gary M Pfeiffer (director) sold 42,643 shares at 85.09 per share price.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Quest Diagnostics Inc was Initiated by Deutsche Bank on Jan 18, 2017 to Buy, Price Target of the shares are set at $108.Quest Diagnostics Inc was Upgraded by Mizuho on Jan 3, 2017 to Buy, Price Target of the shares are set at $103.Quest Diagnostics Inc was Upgraded by Goldman to Buy on Dec 12, 2016.
Quest Diagnostics Inc Last issued its quarterly earnings results on Jan 26, 2017. The company reported $1.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.04. Analyst had a consensus of $1.27. The company had revenue of $1861.00 million for the quarter, compared to analysts expectations of $1859.20 million. The companys revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.29 EPS.
Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.